The Pharmacology Core will provide analytical, drug metabolism and parmacokinetic services with the aim of relating drug (or appropriate metabolite) concentrations to treatment outcome. We specifically propose to support seven projects in the renewal period. As examples, we will assist in the search for a relationship between actual exposure to active metabolites of cyclophosphamide and organ toxicity (Project 5); support a comparison of marrow versus peripheral blood stem cell transplantation in patients whose busulfan levels will not be allowed to fall below 900 ng/mL, with relapse as the primary end point and the definition of a relationship between elevated busulfan levels and organ toxicity as the secondary endpoint (Projects 1 and 6); assist in the determination of a relationship between ganciclovir exposure and neutropenia in the early post-engraftment period (Project 7); and provide pharmacokinetic support to Phase I/II and Phase III trials of mofetil mycophenolate (Project 3). In some instances (e.g., Project 5); we propose to identify the causes of interpatient variability in actual exposure to active compounds at a given dose of drug in order to develop intervention strategies to minimize untoward effects and maximize desired outcome. The Pharmacology Core also will be available to address special clinical pharmacology needs that may arise in Program components in order to implement new initiatives. By establishing a central facility for planning and coordination of sampling protocols and the analytical processing of the many blood and other and other samples involved, the analytical and pharmacokinetic precision and information needed to accomplish the proposed research will be assured.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA018029-24S1
Application #
6217294
Study Section
Project Start
1998-12-01
Project End
1999-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
24
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications